Ping An Securities: Maintaining the “Recommended” Rating of Hewang Pharmaceutical (00013.HK), 2023 results are in line with expectations
Hutchison Pharmaceutical (0013.HK): 23-year performance is in line with expectations, intensive catalysis in the global innovation pipeline
Hehuang Pharmaceutical (0013.HK): Major Indications Approved and Expected to Continue to Catalyze Fruquintinib's Entry into the Blue Ocean of Gastric Cancer
Hewang Pharmaceutical (00013.HK): Small Molecule Drug Pioneers Turn Losses into Profit Turning Point
Bank Rating | Lyon: Raising BeiGene's Target Price to HK$138.5, Reiterating the “Buy” Rating
Dongwu Securities: Maintaining Hewang Pharmaceutical's (00013) “buy” rating, and sevolitinib is expected to be listed in the US this year
Hutchison Pharmaceutical (0013.HK): Performance is in line with expectations, sales are expected to grow steadily
Huhuang Pharmaceutical (0013.HK): Fruquintinib successfully marketed in the US, and sevotinib will submit an NDA as soon as the end of 2024
Hehuang Pharmaceutical (0013.HK): Fruquintinib dosage can be expected to soon go overseas
HUTCHMED(13.HK):A FRUITFUL 2024 ON THE WAY
Hutchison Pharmaceutical (0013.HK): Performance is in line with expectations, and the US NDA for Savolitinib
Hehuang Pharmaceutical (00013.HK): Steady growth in sales and rapid overseas release of fruquintinib
HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
Hehuang Pharmaceutical (00013.HK): Fruquintinib in the US has begun to focus on clinical progress in the core pipeline
Hehuang Pharmaceutical (00013.HK): SYK inhibitors, pioneers of small-molecule targeted drugs, are expected to be approved within the year
Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside
Hehuang Pharmaceutical (0013.HK): FRUTIGA research data shows that fruquintinib has a high probability of being approved for second-line gastric cancer
Huhuang Pharmaceutical (00013.HK) Dynamic Review: Fruquintinib Global Approval Process Smooth, US Sales Volume
Hehuang Pharmaceutical (00013.HK): Solepinib's fourth self-developed innovative drug is expected to be approved within the year
Hehuang Pharmaceutical (0013.HK): Solepinib's marketing application accepted, BIC varieties highlight potential to go overseas
No Data